Vinblastine Injection

— THERAPEUTIC CATEGORIES —
  • Breast cancer
  • Gynecologic cancers
  • Kaposi's sarcoma
  • Leukemias, lymphomas, and other hematologic cancers
  • Prostate and other male cancers
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Vinblastine Injection Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Vinblastine (as sulfate) 1mg/mL; soln for IV inj or infusion; contains benzyl alcohol.

    Pharmacological Class

    Antimicrotubule agent.

    See Also

    How Supplied

    Pwd—10; Soln—1

    Manufacturer

    Fresenius Kabi USA

    Vinblastine Injection Indications

    Indications

    Less frequently responsive: breast cancer, unresponsive to endocrine surgery and hormonal therapy.

    Vinblastine Injection Dosage and Administration

    Adult

    See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

    Children

    Not recommended.

    Vinblastine Injection Contraindications

    Contraindications

    Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

    Vinblastine Injection Boxed Warnings

    Not Applicable

    Vinblastine Injection Warnings/Precautions

    Warnings/Precautions

    For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

    Vinblastine Injection Pharmacokinetics

    See Literature

    Vinblastine Injection Interactions

    Interactions

    May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

    Vinblastine Injection Adverse Reactions

    Adverse Reactions

    Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

    Vinblastine Injection Clinical Trials

    See Literature

    Vinblastine Injection Note

    Not Applicable

    Vinblastine Injection Patient Counseling

    See Literature

    Vinblastine Injection Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Vinblastine (as sulfate) 1mg/mL; soln for IV inj or infusion; contains benzyl alcohol.

    Pharmacological Class

    Antimicrotubule agent.

    See Also

    How Supplied

    Pwd—10; Soln—1

    Manufacturer

    Fresenius Kabi USA

    Vinblastine Injection Indications

    Indications

    Less frequently responsive: choriocarcinoma resistant to other chemotherapy.

    Vinblastine Injection Dosage and Administration

    Adult

    See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

    Children

    Not recommended.

    Vinblastine Injection Contraindications

    Contraindications

    Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

    Vinblastine Injection Boxed Warnings

    Not Applicable

    Vinblastine Injection Warnings/Precautions

    Warnings/Precautions

    For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

    Vinblastine Injection Pharmacokinetics

    See Literature

    Vinblastine Injection Interactions

    Interactions

    May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

    Vinblastine Injection Adverse Reactions

    Adverse Reactions

    Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

    Vinblastine Injection Clinical Trials

    See Literature

    Vinblastine Injection Note

    Not Applicable

    Vinblastine Injection Patient Counseling

    See Literature

    Vinblastine Injection Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Vinblastine (as sulfate) 1mg/mL; soln for IV inj or infusion; contains benzyl alcohol.

    Pharmacological Class

    Antimicrotubule agent.

    See Also

    How Supplied

    Pwd—10; Soln—1

    Manufacturer

    Fresenius Kabi USA

    Vinblastine Injection Indications

    Indications

    Frequently responsive: palliative treatment of Kaposi's sarcoma.

    Vinblastine Injection Dosage and Administration

    Adult

    See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

    Children

    Not recommended.

    Vinblastine Injection Contraindications

    Contraindications

    Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

    Vinblastine Injection Boxed Warnings

    Not Applicable

    Vinblastine Injection Warnings/Precautions

    Warnings/Precautions

    For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

    Vinblastine Injection Pharmacokinetics

    See Literature

    Vinblastine Injection Interactions

    Interactions

    May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

    Vinblastine Injection Adverse Reactions

    Adverse Reactions

    Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

    Vinblastine Injection Clinical Trials

    See Literature

    Vinblastine Injection Note

    Not Applicable

    Vinblastine Injection Patient Counseling

    See Literature

    Vinblastine Injection Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Vinblastine (as sulfate) 1mg/mL; soln for IV inj or infusion; contains benzyl alcohol.

    Pharmacological Class

    Antimicrotubule agent.

    See Also

    How Supplied

    Pwd—10; Soln—1

    Manufacturer

    Fresenius Kabi USA

    Vinblastine Injection Indications

    Indications

    Frequently responsive: palliative treatment of generalized Hodgkin's disease, lymphocytic lymphoma, histiocytic lymphoma, mycosis fungoides.

    Vinblastine Injection Dosage and Administration

    Adult

    See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

    Children

    See literature. IV use only. Hodgkin's disease: initially 6mg/m2. Adjust dose according to hematologic tolerance.

    Vinblastine Injection Contraindications

    Contraindications

    Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

    Vinblastine Injection Boxed Warnings

    Not Applicable

    Vinblastine Injection Warnings/Precautions

    Warnings/Precautions

    For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

    Vinblastine Injection Pharmacokinetics

    See Literature

    Vinblastine Injection Interactions

    Interactions

    May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

    Vinblastine Injection Adverse Reactions

    Adverse Reactions

    Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

    Vinblastine Injection Clinical Trials

    See Literature

    Vinblastine Injection Note

    Not Applicable

    Vinblastine Injection Patient Counseling

    See Literature

    Vinblastine Injection Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Vinblastine (as sulfate) 1mg/mL; soln for IV inj or infusion; contains benzyl alcohol.

    Pharmacological Class

    Antimicrotubule agent.

    See Also

    How Supplied

    Pwd—10; Soln—1

    Manufacturer

    Fresenius Kabi USA

    Vinblastine Injection Indications

    Indications

    Frequently responsive: palliative treatment of advanced carcinoma of the testis.

    Vinblastine Injection Dosage and Administration

    Adult

    See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

    Children

    See literature. IV use only. Testicular germ cell carcinomas: initially 3mg/m2. Adjust dose according to hematologic tolerance.

    Vinblastine Injection Contraindications

    Contraindications

    Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

    Vinblastine Injection Boxed Warnings

    Not Applicable

    Vinblastine Injection Warnings/Precautions

    Warnings/Precautions

    For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

    Vinblastine Injection Pharmacokinetics

    See Literature

    Vinblastine Injection Interactions

    Interactions

    May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

    Vinblastine Injection Adverse Reactions

    Adverse Reactions

    Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

    Vinblastine Injection Clinical Trials

    See Literature

    Vinblastine Injection Note

    Not Applicable

    Vinblastine Injection Patient Counseling

    See Literature

    • Latest News Your top articles for Wednesday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More